QBIO
Q BioMed Inc. [QBIO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
QBIO Stock Summary
In the News
QBIO Financial details
Company Rating
Buy
Market Cap
14.51K
Income
1.48M
Revenue
15.04K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
11 Apr 2024
P/E
0.04
Forward P/E
-
PEG
-0
P/S
4.83
P/B
-0.01
P/C
-
P/FCF
0.03
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.02
EPS next Y
-
EPS next Q
-
EPS this Y
-95.15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0.98%
ROA
43%
ROE
-27%
ROC
-0.33%
Gross Margin
-450%
Oper. Margin
14212%
Profit Margin
9817%
Payout
38%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0E-4-0.0179
52W High
-
52W Low
-
RSI
45.61
Rel Volume
0.02
Avg Volume
24.79K
Volume
500
Perf Week
-50%
Perf Month
-87.5%
Perf Quarter
-
Perf Half Y
-75%
-
-
-
-
Beta
81.005
-
-
Volatility
0%, 0%
Prev Close
-
Price
0.0001
Change
-
QBIO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-11-30
| Metric | History | 2018-11-30 | 2019-11-30 | 2020-11-30 | 2021-11-30 | 2022-11-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0.01 | 0.01 | |
| Net income per share | -0.67 | -0.78 | -0.62 | -0.33 | -0.02 | |
| Operating cash flow per share | -0.47 | -0.27 | -0.28 | -0.16 | 0.04 | |
| Free cash flow per share | -0.51 | -0.27 | -0.28 | -0.16 | 0.04 | |
| Cash per share | 0.2 | 0.01 | 0.01 | 0.01 | 0 | |
| Book value per share | -0.01 | -0.34 | -0.05 | -0.17 | -0.1 | |
| Tangible book value per share | -0.04 | -0.37 | -0.07 | -0.19 | -0.11 | |
| Share holders equity per share | -0.01 | -0.34 | -0.05 | -0.17 | -0.1 | |
| Interest debt per share | 0.22 | 0.34 | 0.02 | 0.13 | 0.12 | |
| Market cap | 26.78M | 24.06M | 24.38M | 12.11M | 716.11K | |
| Enterprise value | 26.97M | 27.58M | 24.29M | 14.82M | 4.78M | |
| P/E ratio | -2.89 | -2.05 | -1.77 | -1.38 | -1 | |
| Price to sales ratio | 0 | 0 | 812.55 | 61.91 | 2.52 | |
| POCF ratio | -4.15 | -5.86 | -3.91 | -2.81 | 0.37 | |
| PFCF ratio | -3.85 | -5.86 | -3.91 | -2.81 | 0.37 | |
| P/B Ratio | -253.32 | -4.77 | -22.67 | -2.58 | -0.16 | |
| PTB ratio | -253.32 | -4.77 | -22.67 | -2.58 | -0.16 | |
| EV to sales | 0 | 0 | 809.72 | 75.76 | 16.8 | |
| Enterprise value over EBITDA | -2.99 | -3.46 | -1.85 | -2.02 | -18.92 | |
| EV to operating cash flow | -4.18 | -6.72 | -3.9 | -3.44 | 2.46 | |
| EV to free cash flow | -3.88 | -6.72 | -3.9 | -3.44 | 2.46 | |
| Earnings yield | -0.35 | -0.49 | -0.57 | -0.72 | -1 | |
| Free cash flow yield | -0.26 | -0.17 | -0.26 | -0.36 | 2.71 | |
| Debt to equity | -27.18 | -0.73 | -0.09 | -0.65 | -0.89 | |
| Debt to assets | 0.9 | 5.76 | 0.15 | 3.77 | 1.17 | |
| Net debt to EBITDA | -0.02 | -0.44 | 0.01 | -0.37 | -16.08 | |
| Current ratio | 6.28 | 0.04 | 0.13 | 0.08 | 0.01 | |
| Interest coverage | -55.64 | -5.49 | -44.38 | -14.58 | -2.49 | |
| Income quality | 0.7 | 0.4 | 0.46 | 0.52 | -0.95 | |
| Dividend Yield | 0 | 0 | 0.02 | 0.04 | 1.35 | |
| Payout ratio | 0 | 0 | -0.03 | -0.06 | -1.35 | |
| Sales general and administrative to revenue | 0 | 0 | 365.64 | 32.02 | 11.64 | |
| Research and developement to revenue | 0 | 0 | 62.67 | 5.49 | 0.44 | |
| Intangibles to total assets | 0.16 | 0.7 | 0.64 | 0.43 | 0.09 | |
| Capex to operating cash flow | 0.08 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 219.14 | 11.96 | 3.18 | |
| Graham number | 0.34 | 2.43 | 0.82 | 1.13 | 0.19 | |
| ROIC | -3.35 | 6.76 | 13.66 | 4.8 | 2.37 | |
| Return on tangible assets | -3.44 | -61.69 | -61.7 | -19.04 | -0.22 | |
| Graham Net | -0.05 | -0.37 | -0.07 | -0.19 | -0.18 | |
| Working capital | 2.27M | -5.05M | -1.48M | -5.04M | -8.06M | |
| Tangible asset value | -605.73K | -5.5M | -1.48M | -5.04M | -4.92M | |
| Net current asset value | -605.73K | -5.5M | -1.48M | -5.04M | -8.06M | |
| Invested capital | -27.18 | -0.73 | -0.09 | -0.65 | -0.89 | |
| Average receivables | 0 | 0 | 0 | 40.05K | 45.82K | |
| Average payables | 427.88K | 522.14K | 686.9K | 1.03M | 1.74M | |
| Average inventory | 0 | 0 | 0 | 11.13K | 11.13K | |
| Days sales outstanding | 0 | 0 | 0 | 149.47 | 14.81 | |
| Days payables outstanding | 0 | 4.76K | 808.07 | 1.99K | 2.65K | |
| Days of inventory on hand | 0 | 0 | 0 | 32.9 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 2.44 | 24.65 | |
| Payables turnover | 0 | 0.08 | 0.45 | 0.18 | 0.14 | |
| Inventory turnover | 0 | 0 | 0 | 11.09 | 20158171.31B | |
| ROE | 87.69 | 2.33 | 12.82 | 1.87 | 0.16 | |
| Capex per share | -0.04 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-08-31 for Q3
| Metric | History | 2022-08-31 | 2022-11-30 | 2023-02-28 | 2023-05-31 | 2023-08-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.02 | 0.03 | -0.01 | 0 | 0 | |
| Operating cash flow per share | -0.01 | 0.03 | 0 | 0 | 0 | |
| Free cash flow per share | -0.01 | 0.03 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | -0.16 | -0.05 | -0.06 | 0 | 0 | |
| Tangible book value per share | -0.17 | -0.06 | -0.06 | 0 | 0 | |
| Share holders equity per share | -0.16 | -0.05 | -0.06 | 0 | 0 | |
| Interest debt per share | 0.09 | 0.05 | 0.04 | 0 | 0 | |
| Market cap | 1.3M | 1.35M | 1.3M | 0 | 0 | |
| Enterprise value | 4.94M | 5.41M | 5.36M | 0 | 0 | |
| P/E ratio | -0.4 | 0.15 | -0.39 | 0 | 0 | |
| Price to sales ratio | 49.56 | 107.64 | 521.91 | 0 | 0 | |
| POCF ratio | -5.44 | 0.51 | -9.44 | 0 | 0 | |
| PFCF ratio | -5.44 | 0.51 | -9.44 | 0 | 0 | |
| P/B Ratio | -0.18 | -0.29 | -0.2 | 0 | 0 | |
| PTB ratio | -0.18 | -0.29 | -0.2 | 0 | 0 | |
| EV to sales | 187.93 | 431.53 | 2.15K | 0 | 0 | |
| Enterprise value over EBITDA | -6.39 | 2.09 | -12.4 | 0 | 0 | |
| EV to operating cash flow | -20.63 | 2.03 | -38.82 | 0 | 0 | |
| EV to free cash flow | -20.63 | 2.03 | -38.82 | 0 | 0 | |
| Earnings yield | -0.62 | 1.71 | -0.63 | 0 | 0 | |
| Free cash flow yield | -0.18 | 1.98 | -0.11 | 0 | 0 | |
| Debt to equity | -0.52 | -0.89 | -0.63 | 0 | 0 | |
| Debt to assets | 7.58 | 1.17 | 1.18 | 0 | 0 | |
| Net debt to EBITDA | -4.7 | 1.56 | -9.39 | 0 | 0 | |
| Current ratio | 0.02 | 0.01 | 0 | 0 | 0 | |
| Interest coverage | -3.25 | 9.34 | -1.61 | 0 | 0 | |
| Income quality | 0.3 | 1.16 | 0.19 | 0 | 0 | |
| Dividend Yield | 0 | 0.34 | 0.08 | 0 | 0 | |
| Payout ratio | 0 | 0.2 | -0.13 | 0 | 0 | |
| Sales general and administrative to revenue | 27.41 | 37.95 | 175.93 | 0 | 0 | |
| Research and developement to revenue | 0.79 | 1.77 | 1.08 | 0 | 0 | |
| Intangibles to total assets | 0.63 | 0.09 | 0.08 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 6.04 | 5.13 | 6.41 | 0 | 0 | |
| Graham number | 0.26 | 0.18 | 0.1 | 0 | 0 | |
| ROIC | 0.23 | -5.08 | 0.22 | 0 | 0 | |
| Return on tangible assets | -4.36 | 0.72 | -0.26 | 0 | 0 | |
| Graham Net | -0.17 | -0.1 | -0.09 | 0 | 0 | |
| Working capital | -7.55M | -8.06M | -9.87M | 0 | 0 | |
| Tangible asset value | -7.55M | -4.92M | -6.73M | 0 | 0 | |
| Net current asset value | -7.55M | -8.06M | -9.87M | 0 | 0 | |
| Invested capital | -0.52 | -0.89 | -0.63 | 0 | 0 | |
| Average receivables | 42.92K | 11.54K | 5.77K | 0 | 0 | |
| Average payables | 2.02M | 2.11M | 2.19M | 1.13M | 0 | |
| Average inventory | 22.55K | 11.34K | 0 | 0 | 0 | |
| Days sales outstanding | 39.52 | 82.82 | 0 | 0 | 0 | |
| Days payables outstanding | 2.82K | 2.39K | 81.09K | 0 | 0 | |
| Days of inventory on hand | 30.72 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 2.28 | 1.09 | 0 | 0 | 0 | |
| Payables turnover | 0.03 | 0.04 | 0 | 0 | 0 | |
| Inventory turnover | 2.93 | 5511439.47B | 0 | 0 | 0 | |
| ROE | 0.11 | -0.5 | 0.13 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
QBIO Frequently Asked Questions
What is Q BioMed Inc. stock symbol ?
Q BioMed Inc. is a US stock , located in New york of Ny and trading under the symbol QBIO
What is Q BioMed Inc. stock quote today ?
Q BioMed Inc. stock price is $0.0001 today.
Is Q BioMed Inc. stock public?
Yes, Q BioMed Inc. is a publicly traded company.
Company Profile
- Volume Average 24.79K
- Market Capitalization 14.51K
- Employee 3
- CEO Mr. Denis D. Corin
- Headquarters New York,NY,US
- IPO Date 2015-06-17
-
Website
https://www.qbiomed.com 
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
